Research
Hormonal
Fat-free mass (FFM) and resting metabolic rate (RMR) are primary determinants of daily energy intake and meal size, challenging the adipocentric model that focuses solely on fat mass and leptin.
Building muscle (FFM) increases your metabolic rate and hunger, which is a natural physiological response. This is not a failure of willpower but a biological drive to fuel your larger body.
GoodSupportsHIGH confidence
Contrary to what many would have expected, a positive association was observed between FFM and daily EI, and also with meal size... RMR was a significant determinant of the size of a self-determined meal and of daily energy consumed
Why this rating
Supported by multiple cohorts and independent data sets.
Source
Appetite control and energy balance: impact of exercise
John E. Blundell et al. · Obesity Reviews · 2015
DOI 10.1111/obr.12257
narrative_reviewCited 338×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Long-term exercise produces a dose-dependent reduction in body weight and fat mass, refuting the media narrative that exercise nullifies energy expenditure through compensatory hunger.Strong
- Individual responses to exercise are highly variable (ranging from significant fat loss to weight gain) due to heterogeneous compensatory increases in energy intake and changes in body composition.Good
- Exercise improves postprandial satiety signaling (satiety quotient) but increases fasting hunger, leading to a net compensatory increase in energy intake that partially offsets energy expenditure.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →